ConV2X Smart Tech Transformation in Healthcare & Life Sciences 2026

We have misdiagnosed the problem in American healthcare. Rising costs, poor outcomes, and system fragility are not the disease — they are symptoms. This keynote reframes the debate: where the real failures lie, what the data actually show, and what genuine reform requires. A provocative, evidence-based call to action.

AI and advanced data systems are moving upstream into clinical development, trial design, patient identification, evidence generation, and the relationship between life sciences and care delivery. Where are they creating measurable value? How should new forms of evidence be validated? And what changes when increasingly intelligent systems become part of the scientific and clinical-development process?

A rapid level set of the developments changing healthcare and life sciences, what mattered over the past 12 months, and the signals likely to matter most in 2027.

The question is no longer whether virtual care, remote monitoring, and digital health can be deployed. It is where they measurably improve care. Leaders examine clinical outcomes, adoption, workflow integration, patient engagement, equity, and the evidence required to move from promising technology to sustainable models of care.

COVID-19 exposed how slowly we see biological threats coming, and how hard it is to act once we do. Years later, measles is surging again, bird flu is spreading in animals, and AI is changing both how threats can be created and how early they can be caught. From emerging infectious diseases and zoonotic threats to digital surveillance and AI-enabled detection, leaders will examine whether public-health, hospital, and technology infrastructure can identify and respond to the next threat before it becomes the next crisis.

Healthcare is moving from AI that answers questions to AI that takes action. What happens when agents coordinate care, initiate workflows, monitor conditions, or act across clinical and enterprise systems? Where must human authority remain? What happens when autonomous systems interact? When something goes wrong, who owns the decision?

AI is moving from administrative assistance into clinical decision-making, diagnostics, and patient-facing care. Where does software become a medical device? What evidence should be required before deployment? How should leaders interpret approval, explainability, bias, model risk, and clinical responsibility? And when an AI-supported decision causes harm, who is accountable?

A practical discussion about moving from impressive models to AI embedded into dynamic clinical practice that measurably improves clinical decisions, workflows, and patient outcomes — and how to sustain it responsibly. Three questions frame the discussion:

Integrating Image-Based Artificial Intelligence in the Operating Room: Enhancing Safety and Efficiency While Navigating Legal and Ethical Considerations
DOI: 10.30953/thmt.v10.578

Where is capital chasing hype? Which healthcare and life-sciences problems are actually worth solving? What evidence should investors demand? Investors, founders, clinicians, and healthcare leaders examine what can create durable value — and what the market should stop funding.

Selected innovators present technologies addressing consequential healthcare and life-sciences problems. Investor and audience discussion followed by networking and reception. Direct access to potential partners, investors, and decision-makers — creating connections that can lead to funding, pilots, and commercial collaboration. Investors will score pitches confidentially.

Investors share candid observations. Startups are recognized. Conversations and networking continue informally.

Technology alone doesn’t transform healthcare. Decisions about evidence, people, incentives, governance, infrastructure, and implementation do. What separates organizations that accumulate technologies from those that actually improve outcomes — and what must leaders put in place now?

Health AI is crossing borders faster than governance is converging. Different jurisdictions are taking different approaches to safety, accountability, data sovereignty, and algorithmic risk while access remains profoundly uneven. Can global principles coexist with national regulation? Who sets the rules — and who risks being left behind?

AI, connected devices, cloud infrastructure, health data, and increasingly autonomous systems are expanding healthcare’s attack surface. What vulnerabilities are being created from the rapid introduction of these emerging technologies? With the seemingly impossible task of providing security across increasing numbers of attack surfaces, what is the most effective approach for healthcare organizations to take? What can be done when healthcare is becoming more connected and AI-driven?

Virtual care, remote monitoring, connected devices, and digital platforms are extending care beyond hospital walls. What infrastructure makes that clinically useful, interoperable, secure, equitable, and financially sustainable? Leaders examine the connection between hospitals, homes, specialists, patients, devices, and data — and where real-world care still breaks.

The Impact of Digital Health Technologies on Chronic Disease Management
DOI: 10.30953/thmt.v10.556

A candid assessment of health innovation against the measures that ultimately matter: evidence, outcomes, economics, adoption, scalability, and risk. What’s delivering? What’s failing? What needs fixing? And what are organizations continuing to fund despite weak evidence or limited value?

Healthcare has no shortage of innovation. The harder question is whether incentives, reimbursement, cost, access, and investment are aligned with better outcomes. Leaders examine where technology is creating measurable value, where payment and business models break down, what decision-makers should demand before scaling, and what is simply adding cost.

From agentic AI and robotics to digital twins, ambient intelligence, advanced diagnostics, edge AI, synthetic data, and privacy-enhancing technologies — which advances could materially improve care, accelerate research, and transform life sciences? Which are being overhyped or underestimated? Leaders from across disciplines connect emerging capabilities to the decisions that matter now: what to implement, what to validate, what to stop doing, and where to direct capital and leadership attention.